Fellowship · Aurora, CO
Sponsored by University of Colorado School of Medicine
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
The New England journal of medicine · 2025 · 482 citations · Theresa Medina
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Lancet (London, England) · 2024 · 686 citations · Theresa Medina
The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017.
The British journal of dermatology · 2021 · 483 citations · Chante Aksut
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 415 citations · Theresa Medina
Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · 80 citations · Theresa Medina
Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.
Journal of the American Academy of Dermatology · 2021 · 228 citations ·
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Journal for immunotherapy of cancer · 2022 · 311 citations · Theresa Medina
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.
Journal of the National Comprehensive Cancer Network : JNCCN · 2021 · 269 citations · Ryan Lanning